CN109896995A - A kind of carbamide compounds and its for treating gynaecological imflammation in terms of purposes - Google Patents
A kind of carbamide compounds and its for treating gynaecological imflammation in terms of purposes Download PDFInfo
- Publication number
- CN109896995A CN109896995A CN201910229554.1A CN201910229554A CN109896995A CN 109896995 A CN109896995 A CN 109896995A CN 201910229554 A CN201910229554 A CN 201910229554A CN 109896995 A CN109896995 A CN 109896995A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- carbamide compounds
- acid
- gynaecological imflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
A kind of purposes in terms of the present invention relates to carbamide compounds and its for treating gynaecological imflammation, carbamide compounds have formula (I) structure, the compound synthesis is simple, there is significant prevention and treatment effect to treatment gynaecological imflammation especially vaginitis, it can be used as prevention or treat the drug of gynaecological imflammation, the pharmaceutical composition the present invention also provides the preparation method of the carbamide compounds and comprising formula (I) compound.
Description
Technical field
A kind of use in terms of the present invention relates to carbamide compounds, preparation method and composition and for treating gynaecological imflammation
On the way.
Background technique
There is inflammation in gynaecological imflammation, that is, reproductive organs, is the high morbidity of women, clinic common are vaginitis, pelvic inflammatory disease,
Cervicitis, adnexitis, vulvitis etc., and acute inflammation and chronic inflammation can be divided into, it is reported that 80% modern female it is all deep by
The evil of gynaecological imflammation.The vulva of women is without any protection and urethra, anus position are got close to, and urination, defecation all may result in life
Device pollution is grown, and is in vulva under wet environment for a long time, and this is exactly the breeding ground of various bacteria breeds, so this physiology
Structure is difficult to be in the vulva of women for a long time in the state of cleaning, drying, so that the growth and breeding for bacterium has provided
The condition of benefit；In addition, the physiological period of women monthly also will increase a possibility that genitals inflammation infection.Gynaecological imflammation is because of inflammation
Difference and different symptoms can be shown, the state of an illness differs in weight, basic clinical symptoms include pruritus vulvue, abnormal leucorrhea,
Irregular menstruation, frequent micturition, urgent urination, lower abdomen falling inflation etc..At initial stage of the female sex organs by bacterium infection, general symptom is not tight
Weight, predominantly pruritus vulvue are the preferably opportunity for the treatment of at this time, can relatively easily control inflammation.Acute gynaecological imflammation meeting
Involve peritonaeum to be inflamed, thus the feeling that women abdomen can be caused to have an intense pain；And chronic gynaecological imflammation can generally make women
Feel underbelly falling inflation, aching pain in waist and back.Gynaecological imflammation brings dual puzzlement for the physiology of women, psychology, need to actively receive
It checks and treats, the state of an illness is avoided to be further aggravated, treatment is made to become more intractable.Data shows, the whole world annual about 15%
Gynecological tumor is induced by inflammation infection.
Although existing marketed drug treats gynaecological imflammation at present, still need to develop that new effect is good, synthesis is simply controlled
Treat gynaecological imflammation drug.
Summary of the invention
The urea of, synthesis good with therapeutic effect that the main purpose of the present invention is to provide a kind of simply treatment gynaecological imflammation
Class compound, the pharmaceutical composition comprising the compound, the preparation method of carbamide compounds and the carbamide compounds are for controlling
Treat the purposes in gynaecological imflammation.
Shown in the structure of the carbamide compounds such as formula (I):
Wherein, X1 is straight key, CH2、CH2CH2Or CO；
R1, R2 are hydrogen atom, NO2, halogen, CN, hydroxyl, carboxyl, amido, alkyl or alkoxy；
Z1, Z2, Z3 and Z4 are selected from C or N；
M, n is 0-3；
Q is 1-3；
It is further:
X1 is preferably straight key, CH2Or CO；
R1, R2 are preferably hydrogen atom, NO2, halogen, hydroxyl, alkyl or alkoxy；
Z1, Z2, Z3 and Z4 are selected from C or N；
M, n is 1-3；
Q is 1 or 2；
The preferred C1-6 alkyl of alkyl specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl group, tertiary fourth
Base, amyl, isopentyl, hexyl etc.；
The alkoxy is preferably C1-6 alkoxy, specifically includes methoxyl group, ethyoxyl, propoxyl group, isopropoxy, fourth oxygen
Base, isobutoxy, tert-butoxy, amyl oxygroup, isopentyl oxygroup and hexyl oxygroup etc..
Described halogen preferred F, Cl or Br, further preferred F or Cl.
Further, the preferred following compounds of formula (I) compound:
Further, formula (I) compound is preferably following compounds；
On the other hand, the present invention provide above compound with acid be formed by medically acceptable salt.
It can be organic acid or inorganic acid at the acid of salt, such as: with hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid
The salt that equal inorganic acids are formed；With formic acid, acetic acid, propionic acid, trifluoroacetic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid,
The salt that the organic acids such as lactic acid, malic acid, tartaric acid, citric acid, benzene sulfonic acid, p-methyl benzenesulfonic acid are formed.
On the other hand, the present invention provides the preparation method of formula (I) compound.
The isocyanates of formula (II) and the amine of formula (III) in anhydrous organic solvent in -20 DEG C to reacting at room temperature, it is organic
The preferred methylene chloride of solvent, chloroform, toluene, tetrahydrofuran, acetonitrile, DMF or DMSO equal solvent, preferably 1 hour reaction time is extremely
10 hours, solvent is boiled off after the reaction was completed, and methanol is added and methylene chloride carries out being recrystallized to give formula (I) compound, Huo Zhejin
Row column chromatography is isolated and purified to obtain formula (I) compound.
On the other hand, the present invention provides a kind of comprising on formula (I) compound or its medically acceptable salt and pharmaceutics
The pharmaceutical composition of acceptable carrier or excipient.
The medically acceptable salt of any of the above-described compound medicine of the present invention, including the salt formed with inorganic acid, such as hydrochloric acid, hydrogen
Bromic acid, phosphoric acid, the salt of sulfuric acid etc.；The salt formed with organic acid, such as acetic acid, trifluoroacetic acid, citric acid, formic acid, maleic acid, grass
The salt of acid, succinic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, ascorbic acid, malic acid, methanesulfonic acid or toluenesulfonic acid etc.；
Amino-acid salt, such as arginine salt, aspartate, glutamate, lysine salt.These acid-addition salts can be according to any logical
It is prepared with method.
On the other hand, the present invention provide a kind of formula (I) compound as prevent or treatment gynaecological imflammation in terms of purposes.
The formula (I) or compound of inventive compound or its medically acceptable salt can be made pharmaceutically acceptable
Any dosage form, it is characterised in that including one or more pharmaceutical carriers and/or diluent.The preferably oral system of the preparation
Agent, injection, lotion, gelling agent, suppository, ointment etc..Wherein unit formulation contains general formula (I) compound represented 0.01g
~10g as required active constituent, preferably 0.1~5g, can for 0.1g, 0.25g, 0.5g, 0.75g, 1g, 1.25g,
1.5g, 1.75g, 2g, 2.5g, 3g, 4g, 5g etc..
Specific embodiment
Embodiments of the present invention are described in detail by the following examples, however, the present invention is not limited thereto.
Embodiment 1
1.8g (15mmol) 2- pyridine isocyanates is weighed in 100mL round-bottomed bottle, 50mL anhydrous methylene chloride is added, then
1.5g (15mmol) cyclopentanemethylamine is added, is stirred to react 2h at room temperature.After reaction, vacuum revolving removes solvent, uses
5ml dichloromethane solvent is dissolved, and methanol is then slowly added dropwise, and until solid no longer is precipitated substantially, filtration drying is obtained
White solid 3.1g (14.2mmol), yield 95.2%.
1H-NMR(400MHz,CDCl3) δ 8.11 (d, 1H), 7.44 (m, 1H), 6.60-6.68 (m, 2H), 6.0 (s, 2H),
3.12 (d, 2H), 2.13 (m, 1H), 1.47-1.51 (m, 8H)；13C-NMR(100MHz,CDCl3) δ 161.1,157.7,148.9,
138.0,113.0,108.9,49.3,36.8,27.0,27.1,23.1,23.2；ESI-MS m/z 220.28[M+H]+。
Embodiment 2
The fluoro- 2- pyridine isocyanates of 2.1g (15mmol) 4- is weighed in 100mL round-bottomed bottle, the anhydrous dichloromethane of 50mL is added
Alkane adds -2 bases of 1.5g (15mmol) pyrrolidines-methylamine, is stirred to react 1h at room temperature.After reaction, vacuum revolving is removed
Solvent is removed, is dissolved with 5ml dichloromethane solvent, methanol is then slowly added dropwise, until solid no longer is precipitated substantially, mistake
It is filtered dry dry white solid 3.2g (13.6mmol), yield 90.8%.
1H-NMR(400MHz,CDCl3) δ 7.82 (s 1H), 7.15 (d, 1H), 6.88 (d, 1H), 6.1 (s, 2H), 3.37
(m, 1H), 3.24 (d, 2H), 2.75 (m, 1H), 2.01 (s, 1H), 1.55-1.59 (m, 4H)；13C-NMR(100MHz,CDCl3)δ
157.7,157.2,149.2,137.4,125.0,109.8,58.3,51.2,44.6,27.1,23.2；ESI-MS m/z
239.12[M+H]+。
Embodiment 3
2.3g (15mmol) 4- Chloro-2-Pyridyle isocyanates is weighed in 100mL round-bottomed bottle, the anhydrous dichloromethane of 50mL is added
Alkane adds 1.3g (15mmol) amido pentamethylene, is stirred to react 3h at room temperature.After reaction, vacuum revolving removes molten
Agent is dissolved with 8ml dichloromethane solvent, methanol is then slowly added dropwise, and until solid no longer is precipitated substantially, is crossed and is filtered dry
It is dry to obtain white solid 3.4g (14.2mmol), yield 94.5%.
1H-NMR(400MHz,CDCl3) δ 7.82 (s 1H), 7.15 (d, 1H), 6.88 (d, 1H), 6.1 (s, 2H), 3.37
(m, 1H), 3.24 (d, 2H), 2.75 (m, 1H), 2.01 (s, 1H), 1.55-1.59 (m, 4H)；13C-NMR(100MHz,CDCl3)δ
157.7,157.2,149.2,137.4,125.0,109.8,58.3,51.2,44.6,27.1,23.2；ESI-MS m/z
239.12[M+H]+。
Embodiment 4
1.8g (15mmol) 2- pyridine isocyanates is weighed in 100mL round-bottomed bottle, 50mL anhydrous methylene chloride is added, then
1.7g (15mmol) cyclopenta formamide is added, is stirred to react 3h at room temperature.After reaction, vacuum revolving removes solvent,
It is dissolved with 10ml dichloromethane solvent, ethyl alcohol is then slowly added dropwise, until solid no longer is precipitated substantially, filtration drying
It obtains white solid 3.2g (13.7mmol), yield 91.4%.
1H-NMR(400MHz,CDCl3) δ 11.0 (bs, 1H) 8.11 (d, 1H), 7.44 (m, 1H), 6.70 (d, 1H), 6.60
(m, 1H), 6.0 (s, 1H), 2.45 (m, 1H), 1.51-1.75 (m, 8H)；13C-NMR(100MHz,CDCl3) δ 178.3,161.1,
154.7,148.9,138.0,113.0,109.8,40.9,25.3,25.5,22.6,22.5；ESI-MS m/z 234.15[M+H]+。
Embodiment 5
The fluoro- 2- pyridine isocyanates of 2.1g (15mmol) 4- is weighed in 100mL round-bottomed bottle, the anhydrous dichloromethane of 50mL is added
Alkane adds 1.7g (15mmol) cyclopenta formamide, is stirred to react 2h at room temperature.After reaction, vacuum revolving removes
Solvent is dissolved with 6ml dichloromethane solvent, ethyl alcohol is then slowly added dropwise, until solid no longer is precipitated substantially, filtering
Dry white solid 3.5g (13.9mmol), yield 92.7%.
1H-NMR(400MHz,CDCl3) δ 11.5 (bs, 1H) 7.82 (s, 1H), 7.15 (d, 1H), 6.68 (d, 1H), 6.0
(s, 1H), 2.45 (m, 1H), 1.51-1.75 (m, 8H)；13C-NMR(100MHz,CDCl3) δ 178.5,157.2,154.7,
149.2,137.4,125.0,109.8,40.9,25.3,25.5,22.6,22.4；ESI-MS m/z 252.11[M+H]+。
Embodiment 6
2.3g (15mmol) 4- methoxyl group -2- pyridine isocyanates is weighed in 100mL round-bottomed bottle, 50mL anhydrous two is added
Chloromethanes adds 1.9g (15mmol) cyclohexyl formamide, is stirred to react 2h at room temperature.After reaction, vacuum rotates
Solvent is removed, is dissolved with 6ml dichloromethane solvent, ethyl alcohol is then slowly added dropwise, until solid no longer is precipitated substantially,
Filtration drying obtains white solid 3.6g (13.8mmol), yield 91.8%.
1H-NMR(400MHz,CDCl3) δ 10.8 (bs, 1H), 8.08 (s, 1H), 7.07 (d, 1H), 6.85 (d, 1H), 6.2
(s, 1H), 3.73 (s, 3H), 2.38 (m, 1H), 1.44-1.68 (m, 10H)；13C-NMR(100MHz,CDCl3)δ178.3,
154.7,152.7,144.6,136.4,122.3,109.1,56.0,39.0,26.8,26.6,23.9,23.7,26.7；ESI-MS
m/z 264.13[M+H]+。
Embodiment 7
2.3g (15mmol) 4- methoxyl group -2- pyridine isocyanates is weighed in 100mL round-bottomed bottle, 50mL anhydrous two is added
Chloromethanes adds -2 bases of 1.5g (15mmol) pyrrolidines-methylamine, is stirred to react 2h at room temperature.After reaction, vacuum is revolved
Solvent is evaporated off, is dissolved with 6ml dichloromethane solvent, ethyl alcohol is then slowly added dropwise, until no longer precipitation solid is substantially
Only, filtration drying obtains white solid 3.4g (13.4mmol), yield 89.2%.
1H-NMR(400MHz,CDCl3) δ 8.80 (s, 1H), 8.08 (s, 1H), 7.07 (d, 1H), 6.85 (d, 1H), 6.0
(s, 1H), 3.37 (m, 1H), 3.24 (d, 2H), 2.75 (m, 2H), 2.0 (s, 1H), 1.44-1.59 (m, 4H)；13C-NMR
(100MHz,CDCl3) δ 157.7,152.7,144.6,136.4,122.3,109.1,58.3,56.0,51.2,44.6,27.1,
23.2；ESI-MS m/z 251.30[M+H]+。
Embodiment 8
2.3g (15mmol) 4- methoxyl group -2- pyridine isocyanates is weighed in 100mL round-bottomed bottle, 50mL anhydrous two is added
Chloromethanes adds 1.3g (15mmol) amido pentamethylene, is stirred to react 2h at room temperature.After reaction, vacuum revolving is removed
Solvent is removed, is dissolved with 6ml dichloromethane solvent, ethyl alcohol is then slowly added dropwise, until solid no longer is precipitated substantially, mistake
It is filtered dry dry white solid 3.3g (13.9mmol), yield 92.6%.
1H-NMR(400MHz,CDCl3) δ 8.08 (s, 1H), 7.07 (d, 1H), 6.85 (d, 1H), 6.2 (s, 1H), 6.0 (s,
1H), 3.73 (s, 3H), 3.61 (m, 1H), 1.51-1.71 (m, 8H)；13C-NMR(100MHz,CDCl3)δ157.7,152.7,
144.6,136.4,122.3,109.1,56.0,50.8,31.2,31.2,20.1,20.1；ESI-MS m/z 236.13[M+H]+。
Embodiment 9
The fluoro- 2- pyridine isocyanates of 2.1g (15mmol) 4- is weighed in 100mL round-bottomed bottle, the anhydrous dichloromethane of 50mL is added
Alkane adds 1.5g (15mmol) 4- anilinic piperidines, is stirred to react 2h at room temperature.After reaction, vacuum revolving removes molten
Agent is dissolved with 6ml dichloromethane solvent, ethyl alcohol is then slowly added dropwise, and until solid no longer is precipitated substantially, is crossed and is filtered dry
It is dry to obtain white solid 3.1g (13.1mmol), yield 87.2%.
1H-NMR(400MHz,CDCl3) δ 7.82 (s, 1H), 7.15 (d, 1H), 6.68 (d, 1H), 6.2 (s, 1H), 6.0 (s,
1H), 3.60 (m, 1H), 2.74 (m, 4H), 2.0 (s, 1H), 1.72 (m, 4H)；13C-NMR(100MHz,CDCl3)δ157.7,
157.2,149.2,137.4,125.0,109.8,46.0,42.4,42.4,33.4,33.4,；ESI-MS m/z 239.15[M+
H]+。
10 pharmacodynamic test of embodiment
Therapeutic effect to rat vagina inflammation: the female rats of weight 200-250g inject Staphylococcus aureus from vagina
Bacterium (3 × 105) and candida albicans bacterium (1.6 × 10 CFU/ml6CFU/ml mixed bacteria liquid), bacterium solution injection rate are 0.05ml/
100g weight, the next day inoculate 1 time.It takes vaginal fluid to do microscopy, Bacteria Culture respectively, and separates respectively within 5th day and the 7th day
Staphylococcus aureus and candida albicans bacterium out, then be inoculated in culture medium respectively, after cultivation, do bacterial strain identification.Microscopy
And it is positive to infect successful rat that bacterial strain, which is identified,.The successful rat of infection is taken to be randomly divided into 3 groups, control group, this hair
Bright compound group, Ofloxacin ointment group, every group 10.Relative medicine, model are injected separately into each rat vagina of administration group
Saline injection in each rat vagina of control group, 1 time a day, continuous 5 days.Take rat vagina within the 1st day and the 4th day after drug withdrawal
Secretion identified, 2 identification pathogen are that feminine gender is set to and turns out cloudy.Rat was dissected in the 5th day after drug withdrawal, takes vagina sample
It is visually observed.
Vagina sample scores by 3 hyperemia, oedema, bleeding indexs:
0 point is commented without hyperemia, oedema, bleeding；
Vagina mucosa still smoothly has mild hyperaemia, is chosen as 1 point；
The still smooth moderate of vagina mucosa is congested, it is seen that petechial hemorrhage point is chosen as 2 points；
Vagina mucosa is unsmooth, and severe is congested, it is seen that bleeds profusely a little, organizes Mild edema, be chosen as 3 points.With model pair
It is set to 100% (degree of inflammation) according to the score value of group, medicine group can obtain medicine group inflammation inhibiting rate compared with model control group.
| Grouping | Inflammatory score | Inflammation inhibiting rate (%) | Negative conversion rate (%) |
| Control group | 2.67±0.23 | 0 | 0 |
| Compound 1 | 0.2±0.05 | 94.7 | 96 |
| Compound 2 | 0.11±0.04 | 98.9 | 98 |
| Compound 3 | 0.26±0.05 | 92.8 | 91 |
| Compound 4 | 0.41±0.06 | 91.9 | 91 |
| Compound 5 | 0.13±0.04 | 98.2 | 98 |
| Compound 6 | 0.29±0.08 | 91.3 | 91 |
| Compound 7 | 0.15±0.05 | 97.6 | 97 |
| Compound 8 | 0.3±0.07 | 90.6 | 90 |
| Compound 9 | 0.18±0.04 | 96.9 | 96 |
| Ofloxacin | 0.86±0.10 | 82.1 | 82 |
It can be seen from the results above that the compound of the present invention 1-9 has significant therapeutic effect, Ke Yiyong to vaginitis
In the treatment of gynaecological imflammation.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all in essence of the invention
Made any modifications, equivalent replacements, and improvements etc., should all be included in the protection scope of the present invention within mind and principle.
Claims (10)
1. a kind of carbamide compounds or its medically acceptable salt, it is characterised in that shown in structure such as formula (I):
Wherein, X1 is straight key, CH2、CH2CH2Or CO；
R1, R2 are hydrogen atom, NO2, halogen, CN, hydroxyl, carboxyl, amido, alkyl or alkoxy；
Z1, Z2, Z3 and Z4 are selected from C or N；
M, n is 0-3；
Q is 1-3.
2. carbamide compounds according to claim 1, it is characterised in that X1 is straight key, CH2 or CO.
3. carbamide compounds according to claim 1, it is characterised in that R1, R2 are hydrogen atom, NO2, halogen, hydroxyl, alkyl
Or alkoxy.
4. carbamide compounds according to claim 1, it is characterised in that Z1, Z2, Z3 and Z4 are selected from C or N；
M, n is 1-3；Q is 1 or 2.
5. carbamide compounds according to claim 1, it is characterised in that formula (I) compound is following compounds:
。
6. carbamide compounds according to claim 1, it is characterised in that formula (I) compound is following compounds
。
7. a kind of method for preparing carbamide compounds described in claim 1, it is characterised in that the isocyanates and formula of formula (II)
(III) amine in anhydrous organic solvent in -20 DEG C to reacting at room temperature, boil off solvent after the reaction was completed, methanol and two be added
Chloromethanes carries out being recrystallized to give formula (I) compound, or carries out column chromatography and isolated and purified to obtain formula (I) compound
Wherein, each group is as defined in claim 1.
8. a kind of pharmaceutical composition, it is characterised in that the composition include any one of claim 1-6 compound or its medically
Acceptable carrier or excipient on acceptable salt and pharmaceutics.
9. a kind of any one of claim 1-6 compound or its medically acceptable salt are used to prepare prevention or treatment gynaecology is scorching
The purposes in drug in terms of disease.
10. a kind of purposes as claimed in claim 9, it is characterised in that gynaecological imflammation is vaginitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910229554.1A CN109896995A (en) | 2019-03-25 | 2019-03-25 | A kind of carbamide compounds and its for treating gynaecological imflammation in terms of purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910229554.1A CN109896995A (en) | 2019-03-25 | 2019-03-25 | A kind of carbamide compounds and its for treating gynaecological imflammation in terms of purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109896995A true CN109896995A (en) | 2019-06-18 |
Family
ID=66953018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910229554.1A Pending CN109896995A (en) | 2019-03-25 | 2019-03-25 | A kind of carbamide compounds and its for treating gynaecological imflammation in terms of purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109896995A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111116422A (en) * | 2019-12-30 | 2020-05-08 | 西南大学 | Paeonol etherified urea compound with anti-inflammatory activity and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017180323A1 (en) * | 2016-04-12 | 2017-10-19 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
| WO2018227300A1 (en) * | 2017-06-14 | 2018-12-20 | UNIVERSITé LAVAL | Novel urea compounds and bioisosteres thereof and their use for treating inflammation and inflammation-related pathologies |
-
2019
- 2019-03-25 CN CN201910229554.1A patent/CN109896995A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017180323A1 (en) * | 2016-04-12 | 2017-10-19 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
| WO2018227300A1 (en) * | 2017-06-14 | 2018-12-20 | UNIVERSITé LAVAL | Novel urea compounds and bioisosteres thereof and their use for treating inflammation and inflammation-related pathologies |
Non-Patent Citations (5)
| Title |
|---|
| STN INTERNATIONAL，COLUMBUS，USA. AN：111:545.: ""RN 1905851-24-2"", 《DATABASE CA [ONLINE]》 * |
| STN INTERNATIONAL，COLUMBUS，USA. AN：111:545.: ""RN 2198597-69-0"", 《DATABASE CA [ONLINE]》 * |
| STN INTERNATIONAL，COLUMBUS，USA. AN：111:545: ""RN 1906143-89-2"", 《DATABASE CA [ONLINE]》 * |
| TERUKI HONMA等: ""Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design"", 《J. MED. CHEM.》 * |
| WANG LIANG等: ""Pd/C-Catalyzed Domino Synthesis of Urea Derivatives Using Chloroform as the Carbon Monoxide Source in Water"", 《ADVANCED SYNTHESIS & CATALYSIS》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111116422A (en) * | 2019-12-30 | 2020-05-08 | 西南大学 | Paeonol etherified urea compound with anti-inflammatory activity and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100475787C (en) | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | |
| CN101522688B (en) | Novel dithiolopyrrolones and their therapeutical applications | |
| CN102762575A (en) | Multicyclic compounds and methods of use thereof | |
| IL234755A (en) | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections | |
| US9890181B2 (en) | Silicon phthalocyanine complex, preparation method and medicinal application thereof | |
| EP1313699A1 (en) | 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith | |
| WO2016179932A1 (en) | Synthesis and application of bornyl ferulate | |
| NO321606B1 (en) | Pyrrole derivatives and medical composition | |
| CN109896995A (en) | A kind of carbamide compounds and its for treating gynaecological imflammation in terms of purposes | |
| WO2018086242A1 (en) | Ph-sensitive axially-substituted silicon phthalocyanine complex, preparation method therefor, and medical application thereof | |
| CN103992236B (en) | A kind of New Target tropism antineoplastic and preparation method thereof and application | |
| CN106518750A (en) | Carbazole alkamine compound and preparation method thereof and application for parasitic disease resistance | |
| CN109956868B (en) | Phenyl carboxylic acid derivatives, preparation method and application thereof | |
| CN102786536B (en) | Sulbactam amoxicillin amide complex for treatment of acute bacterial infection of pig and synthesis method | |
| CN101230045A (en) | Aromatic triazin derivatives and uses thereof | |
| CN107400126A (en) | Novel oxazolidinone class compound and preparation method thereof and application medically | |
| TW201912624A (en) | (E)-α,β-unsaturated guanamine compound, preparation method and use thereof | |
| EP1157014B1 (en) | Polycyclic 2-amino-dihydrothiazole systems, method for the production thereof and their utilization as medicament | |
| CN104230836A (en) | Phenyloxazole compounds and application thereof to preparation of medicament for treating cancers | |
| CN114380816B (en) | Nitroimidazole compound, pharmaceutical composition and application | |
| CN113549046B (en) | Bisbecklonin S derivative and preparation method and application thereof | |
| CN115960080B (en) | Polycyclic compounds and their use as ghrelin receptor agonists | |
| CN101544634B (en) | 2-phenyl-3-substituted pyrazolo[1,5-a]pyridine derivatives, preparation method and application thereof | |
| CN107417601A (en) | The aryl-pyridine of 2 acid amides sulfonyl of substitution 4,6 with antibacterial activity | |
| WO2022193449A1 (en) | Prodrug of celecoxib, preparation method therefor and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190618 |
|
| RJ01 | Rejection of invention patent application after publication |